409 related articles for article (PubMed ID: 23912457)
1. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
Raina D; Uchida Y; Kharbanda A; Rajabi H; Panchamoorthy G; Jin C; Kharbanda S; Scaltriti M; Baselga J; Kufe D
Oncogene; 2014 Jun; 33(26):3422-31. PubMed ID: 23912457
[TBL] [Abstract][Full Text] [Related]
2. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
3. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
[TBL] [Abstract][Full Text] [Related]
4. FOXO1A is a target for HER2-overexpressing breast tumors.
Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
[TBL] [Abstract][Full Text] [Related]
5. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
[TBL] [Abstract][Full Text] [Related]
6. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer.
Kharbanda A; Rajabi H; Jin C; Raina D; Kufe D
Mol Cancer Res; 2013 Jul; 11(7):714-23. PubMed ID: 23538857
[TBL] [Abstract][Full Text] [Related]
9. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
[TBL] [Abstract][Full Text] [Related]
10. Effect of MUC1 siRNA on drug resistance of gastric cancer cells to trastuzumab.
Deng M; Jing DD; Meng XJ
Asian Pac J Cancer Prev; 2013; 14(1):127-31. PubMed ID: 23534710
[TBL] [Abstract][Full Text] [Related]
11. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
13. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
14. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
Canonici A; Gijsen M; Mullooly M; Bennett R; Bouguern N; Pedersen K; O'Brien NA; Roxanis I; Li JL; Bridge E; Finn R; Siamon D; McGowan P; Duffy MJ; O'Donovan N; Crown J; Kong A
Oncotarget; 2013 Oct; 4(10):1592-605. PubMed ID: 24009064
[TBL] [Abstract][Full Text] [Related]
15. TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line.
Deng X; Fogh L; Lademann U; Jensen V; Stenvang J; Yang H; Brünner N; Schrohl AS
Tumour Biol; 2013 Apr; 34(2):1161-70. PubMed ID: 23334956
[TBL] [Abstract][Full Text] [Related]
16. Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression.
Li G; Zhao L; Li W; Fan K; Qian W; Hou S; Wang H; Dai J; Wei H; Guo Y
Oncotarget; 2014 Sep; 5(18):8317-29. PubMed ID: 25327561
[TBL] [Abstract][Full Text] [Related]
17. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Garrett JT; Sutton CR; Kurupi R; Bialucha CU; Ettenberg SA; Collins SD; Sheng Q; Wallweber J; Defazio-Eli L; Arteaga CL
Cancer Res; 2013 Oct; 73(19):6013-23. PubMed ID: 23918797
[TBL] [Abstract][Full Text] [Related]
18. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
19. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.
Huang C; Park CC; Hilsenbeck SG; Ward R; Rimawi MF; Wang YC; Shou J; Bissell MJ; Osborne CK; Schiff R
Breast Cancer Res; 2011 Aug; 13(4):R84. PubMed ID: 21884573
[TBL] [Abstract][Full Text] [Related]
20. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
